Frontiers in Oncology (Mar 2019)

Nuclear Receptor Coactivator 2 Promotes Human Breast Cancer Cell Growth by Positively Regulating the MAPK/ERK Pathway

  • Mengjiao Cai,
  • Mengjiao Cai,
  • Xin Liang,
  • Xin Liang,
  • Xiao Sun,
  • Xiao Sun,
  • Huan Chen,
  • Yiping Dong,
  • Lingzhi Wu,
  • Lingzhi Wu,
  • Suxi Gu,
  • Suxia Han

DOI
https://doi.org/10.3389/fonc.2019.00164
Journal volume & issue
Vol. 9

Abstract

Read online

As a member of the p160 steroid receptor coactivator (SRC) family, nuclear receptor coactivator 2 (NCOA2) is known to play essential roles in many physiological and pathological processes, including development, endocrine regulation, and tumorigenesis. However, the biological function of NCOA2 in breast cancer is not fully understood. We found that the copy number of the NCOA2 gene was frequently amplified in four breast cancers datasets, varying from 6 to 10%, and the mRNA levels of NCOA2 were also upregulated in 11% of the sequenced cases/patients (TCGA provisional dataset). Next, we confirmed that NCOA2 silencing significantly suppressed cell proliferation in different breast cancer cell lines, by inducing cell cycle arrest and apoptosis. Mechanistically, whole-transcriptome sequencing (RNA-Seq) analysis showed that NCOA2 depletion leads to downregulation of the MAPK/ERK signaling cascade, possibly via downregulating NCOA2's downstream target RASEF. In conclusion, our results suggest NCOA2 as a potential target of therapeutics against breast cancer.

Keywords